

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2801-36

C# M#

FANTO et al

Group Art Unit: 1621

Serial No. 09/533,381

Examiner: Barts

Filed: March 26, 2001

Date: December 19, 2001

Title: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE
PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR
AUTOIMMUNE PATHOLOGIES

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 9 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00

Independent claims after amendment 9 minus highest number
previously paid for 9 (at least 3) = 0 x \$ 84.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)

Terminal disclaimer enclosed, add \$ 110.00

First/second submission after Final Rejection pursuant to 37 C.F.R. 1.129(a) (\$740.00)
 Please enter the previously unentered , filed
 Submission attached

RECEIVED
DEC 21 2001
TECH CENTER 1600/2900

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract
 Applicant claims "small entity" status. Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)

Assignment Recording Fee (\$40.00)


Other: 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
ARC:Isp

NIXON & VANDERHYE P.C.
By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FANTO et al

Atty. Ref.: 2801-36

Serial No. 09/533,381

Group: 1621

Filed: March 26, 2001

Examiner: Barts

For: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES

* * * * *

December 19, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE

TECH CENTER 1600/2900
DEC 21 2001

RECEIVED

Responsive to the Official Action dated December 7, 2001, Paper No. 4, and requirement for restriction presented in it, applicants elect the subject matter of Group II, namely, claims 9, 12 and 15 drawn to a method of preventing or treating septic shock. Specific embodiments of the invention are disclosed in the data given on pages 40-47 of the specification.

Responsive to item 4 of the Official Action, the elected single disclosed species is (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride (ST 1275) which is disclosed in the specification at page 6, line 12, and otherwise identified throughout the specification and data as ST 1275.


This response is made with traverse. The compounds disclosed in the present application are effective in counteracting the aetiopathogenetic role of inflammatory cytokines (see page 1, first paragraph). Inflammatory cytokines are responsible for septic

shock and inflammatory and/or autoimmune pathologies (see page 1, last paragraph to page 2, first paragraph).

Examination on the merits is awaited taking into account the Information Disclosure Statement filed March 26, 2001.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Arthur R. Crawford
Reg. No. 25,327

ARC:lsp
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100